Antengene Corporation Limited
Antengene Corporation Limited has 1 licensing announcement in this dataset, dated 2026-03-03.
- Country / operating region
- China
- Ticker
- 06996.HK
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.antengene.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| ATG-201 | CD19; CD3 | bispecific | preclinical | 2026-03-03 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-03-03 | UCB | ATG-201 | USD 60m | USD 20m | ≈ ≤ USD 1100m | 查無 | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| UCB | Worldwide | Tiered royalties on future net sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無